Warning on Serious and Fatal Reactions to Hepatitis C Drug Incivek | DENENA | POINTS

Warning on Serious and Fatal Reactions to Hepatitis C Drug Incivek

U.S. authorities and Health Canada have issued warnings regarding Incivek, a drug made by Massachusetts pharmaceutical company Vertex Inc. Incivek, or teleprevir, is a drug taken in combination with peginterferon alfa and ribavirin by adult patients with genotype 1 chronic Hepatitis C.

Some patients have developed serious skin reactions after taking Incivek, and some have died. Our Alvin, TX drug injury lawyers emphasize that progressive rashes and systemic symptoms have turned fatal when patients kept using the drug. Incivek was approved for use in 2011. In December, the U.S. FDA had issued warnings due to two deaths and 112 serious skin reactions to the drug.

The serious skin reactions include: Toxic Epidermal Necrolysis, Stevens Johnson Syndrome, and Drug Reaction with Esinophilia and Systemic Symptoms. Incivek, though the subject of serious warnings, has not been pulled from the market. It has been shown to dramatically lower the treatment time and cost for patients with Hepatitis C, which in turn minimizes the impact of associated side effects like anemia and rashes.

Contact our Alvin, TX Drug Injury Lawyers to Report Serious Skin Reactions Related to Incivek

When you’re put on a medication, you need to be informed of all the risks and of the action you need to take if you experience side effects from the drug. At Denena Points, PC, our Alvin, TX drug injury lawyers are very concerned about pharmaceutical products that might cause serious or fatal injuries in patients. Our goal is to reduce the danger of injury from a drug product.

If you or your loved one has been harmed by a serious adverse reaction to Incivek, contact us to report it. We’re available at 281-369-4363 or through our online contact form. We offer a free, no obligation initial legal consultation to discuss your injury and examine your potential eligibility for financial compensation. Call today.